Inhibition of the Transforming Growth Factor-β/Smad Signaling Pathway in the Epithelium of Oral Lichen  by Karatsaidis, Andreas et al.
ORIGINAL ARTICLE
Inhibition of the Transforming Growth Factor-b/Smad Signaling
Pathway in the Epithelium of Oral Lichen
Andreas Karatsaidis, Olav Schreurs,TonyAxeŁ ll,
 Kristen Helgeland, and Karl Schenck
Department of Oral Biology and Department of Clinical Dentistry, Dental Faculty, University of Oslo, Oslo, Norway
The basal cells in epithelium of the erythematous form
of oral lichen display hyperproliferation compared with
normal oral mucosa. In this study we examined
whether this is associated with disrupted production,
activation, or signal transduction of the epithelial
growth inhibitor transforming growth factor (TGF)
b1. In situ immunostaining showed that most epithelial
cells in normal oral mucosa had nuclear and cytoplas-
mic Smad4 and phosphorylated Smad2/3, but expressed
little or no Smad7. Expression of latency-associated
peptide TGF-b1, latent TGF-b binding protein 1,TGF-b
type I receptor, and TGF-b type II receptor was readily
seen, but only very little TGF-b1 was activated. In er-
ythematous oral lichen, basal and lower spinous epithe-
lial layers showed staining for latency-associated
peptide TGF-b1,TGF-b type I receptor, and TGF-b type
II receptor. A band with scanty staining for these mole-
cules, but with marked staining for active TGF-b1, was
seen in the upper spinous and granular layers. Numbers
of epithelial cell nuclei with Smad4 and phosphorylated
Smad2/3 staining were signi¢cantly reduced in erythema-
tous oral lichen compared with normal oral mucosa. Ba-
sal and suprabasal cell layers in erythematous oral lichen
showed strong cytoplasmic Smad7 protein staining, but
in spinous and granular layers Smad7 was localized to
the cell membrane. In situ hybridization showed strong
Smad7 mRNA expression in almost all basal keratino-
cytes in erythematous oral lichen; by contrast, no or oc-
casionally very weak Smad7 mRNA expression was seen
in these cells in normal oral mucosa.The observations in-
dicate that inhibition of the TGF-b/Smad pathway may
account for the hyperproliferation of keratinocytes in er-
ythematous oral lichen. Key words: epithelial proliferation/
keratinocytes/oral mucosa. J Invest Dermatol 121:00 ^00, 2003
O
ral lichen (OL), which includes oral lichenoid re-
actions and oral lichen planus (OLP), is a com-
mon oral disease a¡ecting about 2% of the
populations examined (Axell and Rundquist,
1987; Salonen et al, 1990). Oral lichenoid reactions
are de¢ned as adverse reactions to dental materials, whereas
changes with unknown etiology are termed OLP (Bolewska
et al, 1990). Histologically, oral lichenoid reactions and OLP are
indistinguishable from each other (Bolewska and Reibel, 1989).
The lesions are characterized by a typical band-like mononuclear
in£ammatory in¢ltrate in the connective tissue, dominated byT
lymphocytes (Hedberg et al, 1986). Pathologic changes in the
epithelium include hyperorthokeratosis or parakeratosis, acantho-
sis, atrophy, and liquefaction degeneration of basal cells (Andrea-
sen, 1968; Kramer et al, 1978). Clinically, OL shows white papular,
reticular, erythematous, plaque, and ulcerative forms (Andreasen,
1968; Kramer et al, 1978). Erythematous OL (ERY OL) is one of
the common forms of the disease and is often associated with oral
discomfort in the a¡ected persons (Andreasen, 1968).
In order to maintain the strati¢ed epithelium’s normal anatomy
and thereby its functions, there is a ¢ne-tuned balance between
the continuous proliferation of basal keratinocytes and matura-
tion and cell death of terminally di¡erentiating keratinocytes
(Gandarillas, 2000). Epithelial proliferation and di¡erentiation
are regulated by an intricate signaling network of di¡erent pep-
tides (cytokines/growth factors) produced by keratinocytes them-
selves, stromal cells, and in¢ltrating in£ammatory cells and their
respective receptors (Dotto, 1999; Freedberg et al, 2001). Trans-
forming growth factor b (TGF-b) has been shown to have im-
portant regulatory functions in epithelial proliferation and
di¡erentiation (Roberts, 1998; Ten Dijke et al, 2002). Among the
three TGF-b isoforms, TGF-b1 is known as the most prominent
regulator. TGF-b1 inhibits epithelial cell growth through tran-
scriptional repression of the growth promoting gene c-myc (Pie-
tenpol et al, 1990), and upregulates the cyclin-dependent kinase
inhibitors p15 and p21 (Hannon and Beach, 1994; Datto et al,
1995). This leaves the retinoblastoma protein in a hypo-phos-
phorylated state and thereby retains the cells in the G1 phase
(Weinberg, 1995). TGF-b1 can also induce apoptosis in keratino-
cytes (Min et al, 1999), and a¡ect keratinocyte di¡erentiation by
upregulating the expression of integrins and keratins (Mans-
bridge and Hanawalt, 1988; Jiang et al, 1995; Zambruno et al,
1995). The crucial role of TGF-b1 for epithelial development is
highlighted in studies on transgenic mice: the epidermis of
TGF-b1-null mice displays marked hyperproliferation (Glick
et al, 1993), whereas mice with targeted overexpression of active
TGF-b1 exhibit severely disrupted skin development, leading to
neonatal death (Sellheyer et al, 1993).
Reprint requests to: Andreas Karatsaidis, Department of Oral Biology,
PO Box 1052, Blindern, N-0316 Oslo, Norway. Email: akaratsa@odont.
uio.no
Abbrevations: ERY OL, erythematous oral lichen; LAP-TGF-b1, la-
tency-associated peptide TGF-b1; LTBP-1, latent TGF-b binding protein 1;
NOM, normal oral mucosa; OL, oral lichen; OLP, oral lichen planus;
TbRI,TGF-b type I receptor; TbRII,TGF-b type II receptor.
Manuscript received January 31, 2003; revised June 20, 2003; accepted for
publication July 20, 2003
0022-202X/03/$15.00 . Copyrightr 2003 by The Society for Investigative Dermatology, Inc.
1
TGF-b1 is predominantly secreted as a large latent protein
complex, consisting of the mature (active) TGF-b1 homodimer,
the latency-associated peptide (LAP), and the high molecular
weight latent TGF-b binding protein (LTBP) (Wake¢eld et al,
1988; Miyazono et al, 1991). Extracellularly, latent TGF-b1 is pro-
teolytically cleaved with the release of activeTGF-b1. On the tar-
get cell, active TGF-b1 binds to a hetero-tetrameric complex of
two transmembrane signaling receptors: TGF-b type I (TbRI)
and TGF-b type II (TbRII) receptors (Ebner et al, 1993). TbRII
phosphorylates TbRI upon binding of TGF-b1 (Wrana et al,
1994) and TbRI subsequently phosphorylates either of two intra-
cellular protein homologs, Smad2 or Smad3 (Nakao et al, 1997b).
Phosphorylated Smad2 and Smad3 associate in the cytoplasm
with Smad4 and the resulting complexes translocate to the nu-
cleus, where they modulate transcription in collaboration with
other coactivators and corepressors (Massague, 2000). This signal-
ing pathway, however, can be blocked by binding of Smad7 to
the intracellular domain of the TbRI, which inhibits the phos-
phorylation of Smad2 and Smad3 (Nakao et al, 1997a).
We have previously reported that ERY OL lesions show
epithelial atrophy and hyperproliferation of basal keratinocytes
compared with reticular OL and normal oral mucosa (NOM)
epithelium (Karatsaidis et al, 2003). From studies on transgenic
mice with null expression of Smad3, or active TGF-b1 constitu-
tively targeted to the keratin 10 promoter, or overexpression of
Smad7 (Cui et al, 1995; Ashcroft et al, 1999; He et al, 2002), it is
known that interference with theTGF-b/Smad pathway can cause
such changes. In this study, we show that this pathway is inhib-
ited in ERYOL because, concomitantly with an increased activa-
tion of TGF-b1, there is an increased Smad7 expression and
membrane translocation, and signi¢cantly reduced nuclear accu-
mulation of Smad2, Smad3, and Smad4 in the epithelium of
ERY OL. Parallel to the ¢ndings in transgenic mice, this thus
may be the cause for the epithelial hyperproliferation in ERYOL.
MATERIALS AND METHODS
Specimens Biopsies were taken, after informed consent, from
volunteers with ERY OL (n¼12) or with NOM (n¼11). No distinction
was made between OLP and oral lichenoid reactions. Clinical diagnosis
was made by an experienced clinician (TA), and pathologic diagnosis was
con¢rmed on hematoxylin and eosin sections of the biopsies. The clinical
and histopathologic criteria used were those described by Kramer et al
(1978). Buccal mucosal biopsies were taken from sites that typi¢ed the
clinical diagnosis and character of the lesion. The volunteers were tested
for oral Candida infection using Dentocult dip slides (Orion Diagnostica,
Espoo, Finland) and the biopsies were examined by PAS staining. None
of the patients included in this study showed Candida infection at the time
of biopsy. Biopsies were snap-frozen on dry ice (701C), oriented,
embedded in OCT compound (Sakura Finetek, Tokyo, Japan), and stored
at 801C. Biopsies for in situ hybridization were ¢xed in 4% bu¡er
formaldehyde. Five micron thick sections were cut at 201C in a cryostat
and slides were stored at 201C until used. The study was carried out
according to the Helsinki Declaration’s principles for biomedical research
and approved by the Ethical Committee of Health, Oslo, Norway.
Immunohistology Antibodies against the following proteins were used
in this study: the mature and active TGF-b1 (mouse IgG, 1.25 mg per ml,
BioSource International, Camarillo, CA), LAP (TGF-b1) (goat IgG, 1.3 mg
per ml, R&D, Oxfordshire, UK), LTBP-1 (rabbit IgG, 0.3 mg per ml, a
kind gift from Dr C.-H. Heldin, Ludwig Institute for Cancer Research,
Uppsala, Sweden), keratinocyte transglutaminase (mouse IgG, 0.45 mg per
ml, Biomedical Technologies, Stoughton, MA). The following antibodies
from Santa Cruz Biotechnology (Santa Cruz, CA) were used: TGF-bRI
(rabbit IgG, 0.33 mg per ml), TGF-bRII (rabbit IgG, 0.25 mg per ml),
phosphorylated Smad2/3 (rabbit IgG, 0.25 mg per ml), Smad4 (mouse IgG,
2 mg per ml), Smad7 (goat IgG, 4 mg per ml), plasminogen activator
inhibitor 1 (PAI-1) (mouse IgG, 1 mg per ml).
Single stainings were performed after ¢xation of cryosections in 4%
paraformaldehyde for 20 min, followed by 2 5 min washes in
phosphate-bu¡ered saline (PBS) and preincubation with 0.3% H2O2 for
30 min. Sections were rewashed and incubated in 5% of appropriate
normal serum for 30 min (the species of the normal serum used was
equivalent to the species of the secondary antibody used; see below).
Primary antibodies were diluted in PBS with 1% bovine serum albumin,
applied on the sections, and incubated overnight at 41C. Subsequently, the
sections were washed in PBS and incubated 30 min with the appropriate
secondary biotinylated antibody preparation (horse antimouse IgG, goat
antirabbit IgG, or rabbit antigoat IgG, all diluted 1:200 and all fromVector
Laboratories, Burlingame, CA). After washing in PBS, sections were
incubated with avidinbiotin complex conjugated with horseradish
peroxidase (Vector Laboratories) for 30 min, washed, and ¢nally
developed with 3,30 -diaminobenzidine as substrate (Sigma-Aldrich, St
Louis, MO).
In double stainings, the sections were ¢xed as above, washed in PBS, and
incubated in 10% normal goat serum and 10% normal horse serum for 30
min. Primary antibodies for keratinocyte transglutaminase and LTBP-1
were diluted and incubated for 1 h. Sections were washed again in PBS
followed by incubation of a secondary goat antirabbit biotinylated
antibody preparation (1:200, Vector Laboratories) for 30 min. After
washing, the sections were incubated in Cy3-labeled streptavidin (1:1000,
Amersham Pharmacia Biotech, Uppsala, Sweden) for 30 min. Sections
were again washed, followed by sequential incubation with avidin (10 mg
per ml) and biotin (1 mg per ml), both from Sigma-Aldrich, for 10 min
each, and an incubation of a secondary horse antimouse biotinylated
antibody preparation (1:200, Vector Laboratories) for 30 min. This was
followed by incubation with Cy2-labeled streptavidin (1:1000, Amersham
Pharmacia) for 30 min. Sections were ¢nally washed and counterstained
with DAPI (Molecular Probes, Eugene, OR). Isotype-matched control
antibodies showed no staining with the immunohistologic detection
techniques used.
In situ hybridization After ¢xation in 4% bu¡ered formaldehyde
solution for 24 h, biopsies were processed through graded alcohols,
oriented, and embedded in para⁄n. Four micron thick para⁄n sections
were cut and mounted on polylysine-coated glass slides. Prior to staining,
sections were dewaxed and rehydrated according to standard procedures.
Endogenous peroxidase activity was quenched with 3% H2O2 in
methanol. The sections were then rehydrated with distilled water and
equilibrated in TE-bu¡er (10 mM TrisHCl, 1 mM ethylenediamine
tetraacetic acid, pH 7.6). Permeabilization was performed with proteinase
K (Sigma-Aldrich, 20 mg per ml in TE-bu¡er, 30 min, 371C). Proteolytic
activity was stopped by incubation with glycine in PBS (2 mg per ml).
Sections were post¢xed in 4% paraformaldehyde in PBS for 15 min.
Acetylation was done with freshly prepared triethanolamine bu¡er (100
mM, pH 8) with 0.5% acetic anhydride (2 5 min). Equilibration and
prehybridization were carried out with 5 sodium citrate/chloride bu¡er
(SSC) (10 min, room temperature) and hybridization bu¡er (Dako; 2 h,
52 1C), (DAKO, Glostrup, Denmark) respectively. For hybridization,
sections were incubated for 18 h at 52 1C with biotinylated antisense or
sense probe (GreenStar Biotin10 oligonucleotide probe; antisense, 48 bp
hybridizing to nucleotides 440^487 in the coding sequence of human
Smad7; GeneDetect, Auckland, New Zealand) diluted in hybridization
bu¡er (1 mg per ml). Stringency washes were 2 SSC (1 h, 521C),
2 SSC diluted with 50% formamide (20 min, 521C), 0.1SSC (20 min,
521C). Blocking was done withTris-bu¡ered saline (TBS; 0.1M TrisHCl,
pH 7.5, 0.15 M NaCl) with 1% casein (TBS-C). Further incubations and
washings were then peroxidase-conjugated rabbit antibiotin antibodies
(Dako P5106, 1:100 in TBS-C, 30 min), washing with TBS with 0.05%
Tween 20 (TBS-T), biotinyl-tyramide (Dako GenPoint kit K0620; 8 min),
washing with PBS-T, alkaline phosphatase-conjugated rabbit antibiotin
antibodies (Dako D5107; 1:75 in TBS-C, 30 min). The sections were ¢nally
developed with BCIP/NBT substrate (20 min) and counterstained with
Nuclear Fast Red. All aqueous solutions for in situ hybridizations were
prepared with DEPC-distilled water.
Cell countings Images of sections were captured with a digital camera
using objectives with 20 , 40 , 60 , or 100magni¢cation and
monitored on a 17-inch computer screen by means of an imaging soft-
ware program (Soft Imaging System, Mˇnster, Germany). Cell countings
were made using objectives with 20magni¢cation. For ERY OL speci-
mens, the ¢eld chosen for counting was located over the in£ammatory
cell in¢ltrate. Total numbers of keratinocytes and numbers of immuno-
histochemically stained nuclei were counted in the entire part of the
epithelium visible on the computer screen.
Statistics t tests were used to compare di¡erences between groups.
Di¡erences were considered to be statistically signi¢cant at po0.001.
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RESULTS
An overview of the stainings is presented inTable I.
In NOM, basal, spinous, and granular cell layers showed peri-
nuclear, nuclear, and cytoplasmic staining for LAP-TGF-b1 that
gradually decreased in intensity from the spinous to the outer
epithelial surface (Fig 1a). Cytoplasmic staining for LTBP-1 was
seen in all epithelial cell layers in NOM, and this was strongest in
spinous, granular, and super¢cial cell areas (Fig 1c). Speckled
staining for active TGF-b1 was observed in upper spinous and
granular layers (Fig 1ewith enlargement, showing arrow-marked
spots). Strong con£uent staining for active TGF-b1 was seen in
the outermost super¢cial epithelial cell layer in NOM (Fig 1e).
TbRI andTbRII expression was present as a nuclear, a cell mem-
brane, and a cytoplasmic staining in all NOM epithelial cell
layers (Fig 1g, i). In NOM epithelium, the staining was most in-
tense in basal cell layers for both TbRI and TbRII. The majority
of the cells throughout the epithelium showed nuclear and cyto-
plasmic staining for both phosphorylated Smad2/3 and Smad4
(Fig 1k, m, respectively). NOM epithelium showed areas with
patched weak or no cytoplasmic staining for Smad7 (Fig 1o with
enlargement). In situ hybridization showed only very weak and
scattered nuclear and perinuclear Smad7 mRNA in basal kerati-
nocytes of NOM (Fig 1q; antisense). Control hybridization
(sense) did not show any staining (Fig 1r).
In ERY OL, basal and lower spinous layers showed cytoplas-
mic staining for LAP-TGF-b1, which was especially intense
around cell nuclei (Fig 1b with enlargement). Typically, a band-
like area with only scattered or absent LAP-TGF-b1 staining
was observed in the uppermost spinous and granular cell layers
(Fig 1bwith enlargement).There was strong cytoplasmic staining
for LTBP-1 in basal and lower spinous cell layers (Fig 1d). In
upper spinous and granular epithelial layers, this staining had a
marked pericellular and intercellular location (Fig 1d with enlar-
gement). Active TGF-b1 consistently showed a clear cell mem-
brane/pericellular staining in the granular and upper spinous
epithelial layers, but not in the basal cell layers in ERY OL
epithelium (Fig 1f with enlargement). This band of active TGF-
b1 staining was complementary to the cell layers that displayed
decreased LAP-TGF-b1 staining (compare Fig 1b, f with respec-
tive enlargements). The reduced stores of LAP-TGF-b1 may
therefore be a direct result of depletion of latent TGF-b1 in these
layers as a consequence of increased activation. Cell membrane,
cytoplasmic, and intense perinuclear staining for TbRI and
TbRII was seen (Fig 1h, j, respectively). This staining was
strongly reduced or absent in granular and in upper parts of the
spinous epithelial cell layers, often in a band-like pattern, similar
to that described above for LAP-TGF-b1. Phosphorylated Smad2/3
(Fig 1l with enlargement) and Smad4 (Fig 1nwith enlargement)
stainings revealed signi¢cantly reduced numbers of cells with nu-
clear and/or cytoplasmic staining among keratinocytes in all
epithelial layers in OL compared with epithelial cells in NOM
(Table II, pp0.001, t test). The Smad7 staining pattern in ERY
OL was profoundly altered compared with NOM (Fig 1p with
enlargement). In contrast to the nearly absent Smad7 expression
in NOM, basal and suprabasal cell layers in ERY OL showed
strong cytoplasmic Smad7 staining. In spinous and granular
layers, the Smad7 staining was particularly localized to the cell
membrane. Almost all basal keratinocytes showed strong nuclear
and perinuclear expression of Smad7 mRNA in ERYOL epithe-
lium (Fig 1; antisense). Control hybridization (sense) did not
reveal any staining (Fig 1t).
LTBP-1 has been demonstrated to be targeted to elements of
the extracellular matrix through cross-linking by the enzyme
transglutaminase (Nunes et al, 1997; Verderio et al, 1999). Double
staining for LTBP-1 and keratinocyte transglutaminase in NOM
epithelium showed that LTBP-1 was localized preferentially in
the cytoplasm and keratinocyte transglutaminase in cell mem-
brane/pericellular epithelial areas (Fig 1u). In contrast, double
staining for LTBP-1 and keratinocyte transglutaminase in ERY
epithelium showed a cell membrane/pericellular codistribution
of these molecules in spinous and granular cell layers (Fig 1
(v1^v3)).
Finally, we carried out staining for PAI-1, which is upregulated
byTGF-b through Smad (Dennler et al, 1998). NOM epithelium
showed ample cytoplasmic and pericellular staining in spinous
and granular cell layers (Fig 1w). In contrast, there was very little
staining for PAI-1 in ERYOL epithelium, and this was restricted
to only scattered epithelial cells (Fig 1x).
In sum,TGF-b1was strongly activated in parts of the ERYOL
epithelium, but the signal transduction through Smad appeared
to be blocked by Smad7.This was accompanied by a concomitant
decreased expression of PAI-1 in ERYOL epithelium.
DISCUSSION
The integrity of normal strati¢ed epithelium is maintained by a
balance between proliferation of basal epithelial cells and contin-
uous shedding of terminally di¡erentiated epithelial cells (Jetten
and Harvat, 1997; Gandarillas, 2000). Epithelial and stromal cells
produce an array of cytokines and growth factors that bind to
corresponding receptors on epithelial cells, which upon activation
can have a wide variety of antagonistic and synergistic e¡ects on
keratinocyte proliferation and di¡erentiation (Dotto, 1999; Freed-
berg et al, 2001). In this in situ study, we examined the activation
status of TGF-b1 and its intracellular signaling pathway mediated
through Smad molecules.
In NOM, we disclosed evidence for active nuclear Smad sig-
naling in the epithelium: numerous Smad4 and phosphorylated
Smad2/3 positive nuclei were present, with only sparse signs of
Table I. Summary of speci¢c stainings in NOM and ERYOL
NOM OL
LAP-TGF-b Basal/parabasal layers þ þ þ a þ þ þ
Spinous/granular þ þ þ 0/þ
LTBP-1 Basal/parabasal layers þ þ þ þ þ
Spinous/granular þ þ þ þ þ þ
Active TGF-b Basal/parabasal layers 0 0
Spinous/granular Spots þ þ þ
TbRI Basal/parabasal layers þ þ þ þ þ þ
Spinous/granular þ þ 0/þ
TbRII Basal/parabasal layers þ þ þ þ þ þ
Spinous/granular þ þ 0/þ
pSmad2/3 Basal/parabasal layers þ þ þ 0/þ
Spinous/granular þ þ þ 0/þ
Smad4 Basal/parabasal layers þ þ þ 0/þ
Spinous/granular þ þ þ 0/þ
Smad7 Basal/parabasal layers 7 þ þ þ
Spinous/granular 7 Membrane þ þ þ
Smad7 mRNA Basal/parabasal layers 7 þ þ þ
Spinous/granular 0 0
PAI-1 Basal/parabasal layers þ þ 7
Spinous/granular þ þ þ 7
a0, no staining; 7, very weak staining; þ, weak staining; þ þ, moderate
staining; þ þ þ, strong staining.
Table II. Percentages of cells with nuclei stained for Smad2/3
and Smad4 in epithelium of NOM and ERYOL
(mean7standard deviation)
NOM (n¼11) OL (n¼12)
pSmad2/3 60718 19711
Smad4 56717 20712
Statistical di¡erence between NOM and OL groups (po0.001, t test).
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Smad7 expression. This accords with observations in normal skin
epidermis, where Smad2, Smad3, and Smad4 nuclear staining
also was seen in the epidermal basal, spinous, and granular kera-
tinocytes (He et al, 2001). The Smad activation indicates that this,
by inference, has a physiologic regulatory function of keratino-
cyte proliferation and di¡erentiation. Several factors can trigger
such Smad signaling. (1) Active TGF-b1 could have been a likely
activator, but this was only seen at low levels in the uppermost
spinous and granular epithelial cell layers and not among basal
and suprabasal keratinocytes where it should have been to exert
its growth inhibitory function. This accords with observations
from normal epidermis where it is also absent (Kane et al, 1991).
(2) Growth factors that in£uence epithelial proliferation and dif-
ferentiation by signaling through MAPK (e.g., epidermal growth
factor and hepatocyte growth factor) can mediate activation and
nuclear translocation of Smad2 (de Caestecker et al, 1998). This
type of cross-talk between Smad and MAPK pathways may also
exist in NOM epithelium. (3) Signaling could be induced by
TGF-b2 and/or TGF-b3 (Paterson et al, 2001). This is not likely
because TGF-b2 and TGF-b3 are only expressed in the upper spi-
nous and the granular layers in NOM epithelium (own observa-
tions, data not shown) where any action on growth regulation of
basal cells is unlikely. (4) Signaling could occur through activin,
as activin can regulate keratinocyte di¡erentiation (Beer et al,
2000) and mediate downstream Smad2/3-induced transcription
(Lebrun et al, 1999).
In OL, the normal epithelial structure is severely disrupted,
with changes such as hyperkeratosis, atrophy, and degeneration
of basal cells (Andreasen, 1968; Kramer et al, 1978). In addition,
the epithelium shows an abnormally high proliferation rate in
the basal cell layer in the ERY form of the disease (Karatsaidis
et al, 2003). Such changes could be caused by inhibition of the
growth regulatory activity of TGF-b1. In this study we therefore
examined TGF-b1 signaling in ERY OL at the level of produc-
tion and activation of the ligand, of TbRI and TbRII expression,
and of Smad signal transduction, and we conclude the following.
(1) Production and activation of TGF-b1 are not de¢cient in ERY
OL because there was ample staining for latent TGF-b1
(as shown by the presence of LAP-TGF-b1) and a strong staining
for active TGF-b1 in the upper parts of the spinous layer and in
the granular cell layer. The activation markedly exceeded the
levels seen in NOM, but TGF-b1 activation was con¢ned to the
more super¢cial di¡erentiating cell layers and was not seen
among basal cells where it could have had an antiproliferative
e¡ect. (2) TGF-b signaling is probably not obstructed by de¢-
cient expression of TbRI and TbRII because the receptors were
normally expressed in basal and spinous layers of the ERY OL
epithelium. Incidentally, the upper spinous and granular layers
showed a reduced TbRI/TbRII expression. This could be a
desensitizing/downregulating response to the increased TGF-b1
activitya mechanism that has been documented in vitro (Prime
et al, 1994; Zwaagstra et al, 1999). It has also recently been shown
that Smad7 can be involved in degradation of TGF-b receptors at
the protein level (Kavsak et al, 2000). As Smad7 was located at the
level of the cell membrane in the uppermost spinous and granular
layers in ERY OL, this also could contribute to the reduced ex-
pression of TbRI and TbRII at this location. (3) There appears to
be blockage of the TGF-b1 signal through Smad2 and Smad3 in
ERY OL, because there were signi¢cantly decreased numbers of
cells with nuclear accumulation of the signaling molecules
Smad2, Smad3, and Smad4 in all epithelial cell layers, concomi-
tant with a marked cell membrane localization of the inhibitory
signaling molecule Smad7. Moreover, Smad7 transcription was
shown to be signi¢cantly upregulated in basal keratinocytes of
ERYOL compared with NOM. Blockage of Smad2 and Smad3
phosphorylation by Smad7 may thus be the cause for the in-
creased proliferation rate in ERY OL epithelium. This notion is
strongly supported by studies in transgenic mice that show that
both Smad3-null mice and mice with overexpression of Smad7
display increased keratinocyte proliferation (Ashcroft et al, 1999;
He et al, 2002). Moreover, transgenic mice with constitutive active
TGF-b1 coupled to the keratin 10 promoter (which targets TGF-
b1 to suprabasal epithelial cell layers) also show epidermal hyper-
proliferation, suprabasal TGF-b1 activation, and epithelial atrophy
(Cui et al, 1995). The ¢ndings in the latter model strongly resem-
ble our observations in ERY OL epithelium. It is likely that a
signaling blockage by Smad7 was in part responsible for the
(then unexpected) increased epithelial proliferation seen in the
keratin-10-TGF-b1 transgenic mice.
The site (i.e., the epithelial layers) where TGF-b1 exerts its ac-
tivity is known to be crucial for the morphology of the epithe-
lium. TGF-b1 activation within the basal cell layer in£icts major
damage to the epithelium: e.g., transgenic mice with constitutive
expression of active TGF-b1 targeted to basal keratinocytes do
not survive because of a total inhibition of basal cell proliferation
(Sellheyer et al, 1993). Other transgenic strains, where latent TGF-
b1 expression was coupled to keratin 14 promoter (which is con-
ditionally activated in basal keratinocytes), showed marked de-
fects in re-epithelialization during wound healing (Yang et al,
2001). This may be the reason whyTGF-b1 during normal wound
healing is activated in a con¢ned compartment of the more
super¢cial epithelial cell layers, at a distance from the proliferative
basal cells (Kane et al, 1991). The observed restricted activation of
TGF-b1 in ERY OL epithelium resembles this pattern. Our
stainings for LTBP-1 and keratinocyte transglutaminase expres-
sion might give a clue to why this activation shows this con¢ne-
ment. In connective tissue, LTBP-1 has a function in targeting
latent TGF-b to the extracellular matrix and transglutaminase
contributes to this process because it cross-links LTBP-1 to extra-
cellular matrix elements (Nunes et al, 1997). Transglutaminase is
not expressed in basal keratinocytes in oral mucosa (Ta et al,
1990;present observations) and if transglutaminase and LTBP-1
have a similar TGF-b targeting function in epithelium as in con-
nective tissue, this might explain the con¢nement of the TGF-b1
activation. Therefore, as long as the TGF-b1 activity remains
compartmentalized as in the present ERYOL biopsies, the lesion
could be regarded as a wound that is trying to heal normally but
is kept in an unresolved state by the chronic in£ammatory in¢l-
trate (see below). If TGF-b1, however, would become very
strongly activated and a¡ect the basal cell layers, epithelial prolif-
eration could become so severely inhibited that the lesion then
perhaps might turn into its ulcerative form.
The epithelial di¡erentiation pattern and cell death mode are
disturbed in ERYOL (Karatsaidis et al, 2003), which is the under-
lying cause for the morpho-pathologic changes typical for the
disease. Besides inhibiting epithelial growth, TGF-b1 can a¡ect
epithelial di¡erentiation by regulating, for example, keratin and
integrin expression and apoptosis (Mansbridge and Hanawalt,
1988; Jiang et al, 1995; Zambruno et al, 1995; Min et al, 1999).
Altered epidermal di¡erentiation resembling that in OL can be
seen in transgenic mice in which the TGF-b signaling pathway
was manipulated; mice with overexpressed epidermal Smad7
show acanthosis and hyperkeratosis (He et al, 2002) and keratin-
10-TGF-b1 transgenic mice in which the epidermis was treated
with 12-O-tetradecanoylphorbol-13-acetate (a hyperplasia indu-
cing agent) acquire pronounced epidermal atrophy (Cui et al,
1995). It is therefore possible that the detected inhibition of the
TGF-b signaling pathway plays a role in the epithelial atrophy
in ERYOL (Karatsaidis et al, 2003).
Based on prospective follow-up studies of large groups of OLP
patients, it has been suggested that OLP can be a premalignant
condition because a small fraction of the initial lesions diagnosed
as plaque or ERY OLP over time developed into cancer
(Holmstrup et al, 1988). Loss of Smad and TGF-b receptor signal-
ing has been observed in cancer cells, and this is associated with
decreased growth inhibitory control of TGF-b (Pasche, 2001).
Even though the TGF-b/Smad signaling blockade was not com-
plete in ERY OL, alterations in this growth inhibitory pathway
might perhaps, in concert with other predisposing factors, play a
role in dysplastic transformation of ERYOL.
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Figure1. Micrographs of immunohistologically stained tissue sections from biopsies obtained from persons with NOM (a, c, e, g, i, k, m, o,
u, w) and patients with OL (b, d, f, h, j, l, n, p, v, x). After immunohistochemical staining the labeled molecules are seen in brown (counterstain with
hematoxylin) and for immuno£uorescence (u, v) the speci¢c molecules are displayed in red and green (overlapping red and green appear yellow; blue nuclear
stain with DAPI). Antibodies used were against (a), (b) LAP-TGF-b1; (c), (d ) LTBP-1; (e), (f ) active TGF-b1 (arrows in (e) indicate spotted staining); (g), (h)
TbRI; (i), (j ) TbRII; (k), (l ) phoshorylated Smad2/3; (m), (n) Smad4; (o), (p) Smad7; (q), (r) LTPB-1 in red, keratinocyte transglutaminase in green (position of
the basement membrane indicated with white broken lines); (w), (x) mature PAI-1; in situ hybridization for Smad7 (q, r, s, t; labeled molecules are in blue;
counterstain with red). Low magni¢cation pictures (lettered a to x, except for q, r, s, t) were obtained with a 20 objective (scale bar: 100 mm). High magni-
¢cation pictures (without lettering) were taken with a 60 objective, except for enlargements (e) and (k), which were taken with 100 and 40 objectives,
respectively. Micrographs of in situ hybridization (q, r, s, t) were obtained with a 40 objective. Frames of high magni¢cation are connected to their respec-
tive low magni¢cation areas with arrows. Scale bar for £uorescence ¢gures (u, v) is 10 mm.
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Figure1. Continued
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Upregulation of the expression of Smad7 can be caused by
pro-in£ammatory cytokines like interferon-g and tumor necrosis
factor a (Ulloa et al, 1999; Bitzer et al, 2000). These are believed to
be central regulatory cytokines in OL, and are synthesized and
secreted by activated keratinocytes and in£ammatory cells in the
subepithelial in¢ltrate (Yamamoto and Osaki, 1995). Typically,
Smad7 mRNA was observed in the basal keratinocyte layer in
ERY OL. The increased basal cell proliferation in ERY OL
epithelium (Karatsaidis et al, 2003) can thus be due to inhibition
of TGF-b/Smad signaling by Smad7, induced by interferon-g
and tumor necrosis factor a.
TGF-b is a strong upregulator of the transcription of PAI-1 in
human keratinocytes (Keski-Oja and Koli, 1992). Elements in the
PAI-1 promoter that are binding sites for the Smad3Smad4 het-
erodimer have indeed been identi¢ed (Dennler et al, 1998). PAI-1
expression in ERY OL epithelium was strongly reduced, which
indicates a blockage at the functional level of the TGF-b/Smad
signaling pathway.
In sum, these results indicate that there is a functional blockage
of the TGF-b signaling pathway by increased Smad7 expression
and translocation in ERY OL. This may explain the increased
hyperproliferation and the disturbed terminal di¡erentiation of
keratinocytes observed in this disease.
We thank Tannlegesenteret-Bergrdveien 13 in Oslo for help with collection of the
biopsies and Dr. Guttorm Haraldson and Dr. MarjanVeuger for technical advice with
in situ hybridization.
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